Gilead Sciences, Inc.
MCL-1 inhibitors
Last updated:
Abstract:
The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
Status:
Grant
Type:
Utility
Filling date:
23 Apr 2020
Issue date:
27 Apr 2021